RB1 and cancer: While the chemotherapy benefit for RB1-defective or Rbness cancers is a key finding and may be directly applicable to some cancer types, the emerging landscape of TNBC neoadjuvant standard-of-care treatment options that now includes a combination of immunotherapy with carboplatin, taxane, and anthracycline, adds to the complexity of using RBNSig-BC for TNBC (66).